ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 957,57
0,54%
Dow Jones
38 675,68
1,18%
DAX
18 001,60
0,54%
Brent Oil
82,765
0,00%
Bitcoin
63 667,83
-0,35%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NYSE
  6. Genesis Healthcare Inc (GEN)

  7. Genesis Healthcare Inc (GEN) Actualités

GEN

Genesis Healthcare (GEN)

Genesis Healthcare Inc
De:
Trier par:
 Showing the most relevant articles for your search:NYSE:GEN
DateHeureSourceTitreSymboleSociété
24/01/202312h27GlobeNewswire Inc.Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2022NYSE:GENGenesis Healthcare Inc
11/11/202202h49TipRanksRBC Capital Keeps Their Hold Rating on Gen Digital (GEN)NYSE:GENGenesis Healthcare Inc
09/11/202217h01GlobeNewswire Inc.Genmab Announces Financial Results for the First Nine Months of 2022NYSE:GENGenesis Healthcare Inc
03/11/202217h45GlobeNewswire Inc.Genmab Improves Its 2022 Financial GuidanceNYSE:GENGenesis Healthcare Inc
18/10/202212h35GlobeNewswire Inc.Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Third Quarter of 2022NYSE:GENGenesis Healthcare Inc
05/10/202221h56GlobeNewswire Inc.Major Shareholder AnnouncementNYSE:GENGenesis Healthcare Inc
10/08/202217h01GlobeNewswire Inc.Genmab Announces Financial Results for the First Half of 2022NYSE:GENGenesis Healthcare Inc
19/07/202212h33GlobeNewswire Inc.Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Second Quarter of 2022NYSE:GENGenesis Healthcare Inc
18/07/202216h01GlobeNewswire Inc.Genmab Announces That AbbVie Will Submit Marketing Authorization Application to European Medicines Agency for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)NYSE:GENGenesis Healthcare Inc
30/06/202220h24GlobeNewswire Inc.Genmab to Submit Biologics License Application to U.S. Food and Drug Administration for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL)NYSE:GENGenesis Healthcare Inc
09/06/202223h17GlobeNewswire Inc.Genmab Commences New Arbitration Under License Agreement With JanssenNYSE:GENGenesis Healthcare Inc
11/05/202217h01GlobeNewswire Inc.Genmab Announces Financial Results for the First Quarter of 2022NYSE:GENGenesis Healthcare Inc
19/04/202212h29GlobeNewswire Inc.Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2022NYSE:GENGenesis Healthcare Inc
13/04/202223h25GlobeNewswire Inc.Genmab and AbbVie Announce Topline Results for Epcoritamab (DuoBody®-CD3xCD20) From Phase 1/2 Trial in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL)NYSE:GENGenesis Healthcare Inc
08/04/202201h44GlobeNewswire Inc.Genmab Announces the Initial Resolution of its Arbitration with Janssen Relating to their Daratumumab License AgreementNYSE:GENGenesis Healthcare Inc
24/02/202212h01GlobeNewswire Inc.Notice to Convene the Annual General Meeting of Genmab A/SNYSE:GENGenesis Healthcare Inc
16/02/202217h00GlobeNewswire Inc.Genmab Publishes 2021 Annual ReportNYSE:GENGenesis Healthcare Inc
25/01/202212h30GlobeNewswire Inc.Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2021NYSE:GENGenesis Healthcare Inc
04/01/202215h00GlobeNewswire Inc.Genmab and Synaffix Enter into License Agreement for ADC TechnologyNYSE:GENGenesis Healthcare Inc
10/11/202117h00GlobeNewswire Inc.Genmab Announces Financial Results for the First Nine Months of 2021NYSE:GENGenesis Healthcare Inc
04/11/202121h24GlobeNewswire Inc.Genmab Improves its 2021 Financial GuidanceNYSE:GENGenesis Healthcare Inc
19/10/202112h29GlobeNewswire Inc.Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Third Quarter of 2021NYSE:GENGenesis Healthcare Inc
21/09/202120h22GlobeNewswire Inc.Capital Increase in Genmab as a Result of Employee Warrant ExerciseNYSE:GENGenesis Healthcare Inc
20/09/202123h00GlobeNewswire Inc.Genmab and Seagen Announce FDA Accelerated Approval for TIVDAK™ (tisotumab vedotin-tftv) in Previously Treated Recurrent or Metastatic Cervical CancerNYSE:GENGenesis Healthcare Inc
11/08/202117h01GlobeNewswire Inc.Genmab Announces Financial Results for the First Half of 2021NYSE:GENGenesis Healthcare Inc
21/07/202112h31GlobeNewswire Inc.Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Second Quarter of 2021NYSE:GENGenesis Healthcare Inc
22/06/202116h12GlobeNewswire Inc.Genmab Announces that Janssen has Received European Marketing Authorizations for DARZALEX® (daratumumab) Subcutaneous Formul...NYSE:GENGenesis Healthcare Inc
28/05/202122h30Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NYSE:GENGenesis Healthcare Inc
21/05/202115h08GlobeNewswire Inc.Genmab Announces that Janssen has Received Positive CHMP Opinion Recommending DARZALEX® (daratumumab) Subcutaneous (SC) Form...NYSE:GENGenesis Healthcare Inc
05/05/202117h01GlobeNewswire Inc.Genmab Announces Financial Results for the First Quarter of 2021NYSE:GENGenesis Healthcare Inc
 Showing the most relevant articles for your search:NYSE:GEN

Dernières Valeurs Consultées

COIN
ETHUSD
Ethereum
EU
ACA
Credit Agricole
NYSE
DIS
Walt Disney
NYSE
MRK
Merck
NASDAQ
GOOGL
Alphabet
EU
VK
Vallourec
EU
SGO
Cie de SaintGobain
NYSE
JPM
JP Morgan Chase
FTSE
UKX
FTSE 100
NASDAQ
NVDA
NVIDIA
SPI
SP500
S&P 500
EU
GLE
Societe Generale
EU
AI
Air Liquide
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés